Double Medical Technology Inc - Asset Resilience Ratio
Double Medical Technology Inc (002901) has an Asset Resilience Ratio of 12.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Double Medical Technology Inc's Asset Resilience Ratio has changed over time. Check Double Medical Technology Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Double Medical Technology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002901 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥633.43 Million | 12.59% |
| Total Liquid Assets | CN¥633.43 Million | 12.59% |
Asset Resilience Insights
- Moderate Liquidity: Double Medical Technology Inc has 12.59% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Double Medical Technology Inc Industry Peers by Asset Resilience Ratio
Compare Double Medical Technology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Double Medical Technology Inc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Double Medical Technology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.09% | CN¥496.97 Million ≈ $72.72 Million |
CN¥4.92 Billion ≈ $720.57 Million |
+6.18pp |
| 2024-12-31 | 3.91% | CN¥172.75 Million ≈ $25.28 Million |
CN¥4.42 Billion ≈ $646.63 Million |
-5.43pp |
| 2023-12-31 | 9.34% | CN¥433.20 Million ≈ $63.39 Million |
CN¥4.64 Billion ≈ $678.94 Million |
+0.23pp |
| 2022-12-31 | 9.11% | CN¥358.67 Million ≈ $52.48 Million |
CN¥3.94 Billion ≈ $576.18 Million |
-13.66pp |
| 2021-12-31 | 22.77% | CN¥769.71 Million ≈ $112.63 Million |
CN¥3.38 Billion ≈ $494.58 Million |
+3.72pp |
| 2020-12-31 | 19.05% | CN¥504.01 Million ≈ $73.75 Million |
CN¥2.65 Billion ≈ $387.14 Million |
+11.96pp |
| 2019-12-31 | 7.09% | CN¥158.74 Million ≈ $23.23 Million |
CN¥2.24 Billion ≈ $327.60 Million |
-1.06pp |
| 2018-12-31 | 8.15% | CN¥135.75 Million ≈ $19.86 Million |
CN¥1.67 Billion ≈ $243.65 Million |
+8.06pp |
| 2017-12-31 | 0.09% | CN¥1.29 Million ≈ $188.22K |
CN¥1.39 Billion ≈ $203.16 Million |
-22.92pp |
| 2016-12-31 | 23.02% | CN¥165.50 Million ≈ $24.22 Million |
CN¥719.06 Million ≈ $105.22 Million |
+10.96pp |
| 2015-12-31 | 12.06% | CN¥67.70 Million ≈ $9.91 Million |
CN¥561.32 Million ≈ $82.14 Million |
+7.68pp |
| 2014-12-31 | 4.38% | CN¥23.90 Million ≈ $3.50 Million |
CN¥545.28 Million ≈ $79.79 Million |
+4.33pp |
| 2013-12-31 | 0.05% | CN¥154.13K ≈ $22.55K |
CN¥296.19 Million ≈ $43.34 Million |
-- |
About Double Medical Technology Inc
Double Medical Technology Inc. engages in the research, development, production, and sale of high-value medical consumables in China. The company offers orthopedic trauma implants, spinal implants, joint implants, sports medicine and neurosurgery implants, minimally invasive surgical implants, and dental implants. It also exports its products. The company was formerly known as Xiamen Da Bo Ying J… Read more